Press Releases

May 9, 2019
Odevixibat Phase 3 PEDFIC 1 PFIC trial continues to enroll as planned Initiation of additional cohort of PFIC patients in PEDFIC 2 extension trial announced Odevixibat pivotal trial in biliary atresia on track to begin H2 2019 IND cleared to initiate elobixibat Phase 2 trial in NASH Q2 2019
April 1, 2019
BOSTON , April 01, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will present at the following investor conferences in April: H.C. Wainwright & Co.